Arnold & Porter partner Daniel Kracov, co-chair of the firm's Life Sciences and Healthcare Regulatory practice, was recently featured in a Law360 profile discussing the impact COVID-19 has had on the American biomedical and health care landscape, particularly for diagnostic technologies and medical product supply chains. The article is part of a series documenting the legal, regulatory and business effects stemming from COVID-19.
» Read the full Q&A (subscription required).
Originally published 18 May, 2020
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
